Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model

Hepatology Research

Volumn 43, Issue 11, 2013, Pages 1241-1250

  Aihara, Yosuke ^a   Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Kaji, Kosuke ^a   Namisaki, Tadashi ^a   Shirai, Yusaku ^a   Douhara, Akitoshi ^a   Moriya, Kei ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Hepatocarcinogenesis; Liver fibrosis; Non alcoholic steatohepatitis; Renin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALISKIREN; AMINO ACID; ANGIOTENSIN II; BILIRUBIN; GLUTATHIONE TRANSFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; RENIN; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ENZYME PHOSPHORYLATION; GENE EXPRESSION; LIVER CARCINOGENESIS; LIVER FIBROSIS; LIVER WEIGHT; MALE; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; STELLATE CELL;

EID: 84886826434     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12081     Document Type: Article

References (51)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Yasui K, Hashimoto E, Tokushige K etal. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res 2012; 42: 767-773.
3. Kaji K, Yoshiji H, Kitade M etal. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 2008; 22: 801-808.
4. Bell LN, Wang J, Muralidharan S etal. Relationship between adipose tissue insulin resistance and liver histology in NASH: a PIVENS follow-up study. Hepatology 2012; 56: 1311-1318.
5. Loomba R, Abraham M, Unalp A etal. Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951.
6. Kato J, Koda M, Kishina M etal. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med 2012; 30: 107-113.
7. Kawai D, Takaki A, Nakatsuka A etal. Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 2012; 56: 912-921.
8. Imarisio C, Alchera E, Sutti S etal. Adenosine A2a receptor stimulation prevents hepatocyte lipotoxicity and nonalcoholic steatohepatitis (NASH) in rats. Clin Sci (Lond) 2012; 123: 323-332.
9. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660.
10. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
11. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011; 17: 1359-1370.
12. Kitade M, Yoshiji H, Kojima H etal. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983-991.
13. Kitade M, Yoshiji H, Noguchi R etal. Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 5193-5199.
14. Yoshiji H, Kuriyama S, Yoshii J etal. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-1354.
15. Yoshiji H, Kuriyama S, Yoshii J etal. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004; 39: 1517-1524.
16. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
17. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
18. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
19. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127-3139.
20. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485.
21. Berenson A. A cancer drug shows promise, at a price that many can't pay. The New York Times 2006 Feb 15: A1, C2.
22. Ferreira AJ, Santos RA, Bradford CN etal. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010; 55: 207-213.
23. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2009; 20: 1888-1893.
24. Hirose A, Ono M, Saibara T etal. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007; 45: 1375-1381.
25. Kaji K, Yoshiji H, Kitade M etal. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1094-1104.
26. Munshi MK, Uddin MN, Glaser SS. The role of the renin-angiotensin system in liver fibrosis. Exp Biol Med (Maywood) 2011; 236: 557-566.
27. Yoshiji H, Noguchi R, Ikenaka Y etal. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2009; 2: 70.
28. Bataller R, Sancho-Bru P, Ginès P etal. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003; 125: 117-125.
29. Yoshiji H, Kuriyama S, Yoshii J etal. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-750.
30. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002; 23: 348-356.
31. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52.
32. McMurray JJ, Pitt B, Latini R etal. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
33. Lindner T. Aliskiren combined with losartan in diabetes and nephropathy. N Engl J Med 2008; 359: 1068-1069; author reply 9-70.
34. Moniwa N, Varagic J, Ahmad S, VonCannon JL, Ferrario CM. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. Ther Adv Cardiovasc Dis 2012; 6: 15-29.
35. Crespo MJ, Cangiano JL, Altieri PI, Escobales N. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in syrian cardiomyopathic hamsters. J Cardiovasc Pharmacol 2012; 59: 547-552.
36. Yoshiji H, Kuriyama S, Kawata M etal. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-1078.
37. Uraoka M, Ikeda K, Nakagawa Y etal. Prorenin induces ERK activation in endothelial cells to enhance neovascularization independently of the renin-angiotensin system. Biochem Biophys Res Commun 2009; 390: 1202-1207.
38. Saris JJ, 't Hoen PA, Garrelds IM etal. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-571.
39. Sakoda M, Ichihara A, Kaneshiro Y etal. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139-1146.
40. Li CY, Shan S, Huang Q etal. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000; 92: 143-147.
41. Kitade M, Yoshiji H, Kojima H etal. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. Mol Med Report 2008; 1: 543-548.
42. Kaji K, Yoshiji H, Ikenaka Y etal. Possible involvement of angiogenesis in chronic liver diseases: interaction among Renin-Angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem 2012; 19: 1889-1898.
43. Kalluri R, Sukhatme VP. Fibrosis and angiogenesis. Curr Opin Nephrol Hypertens 2000; 9: 413-418.
44. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-1065.
45. Frachon S, Gouysse G, Dumortier J etal. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 2001; 34: 850-857.
46. Nakae D, Yoshiji H, Mizumoto Y etal. High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res 1992; 52: 5042-5045.
47. Nakae D, Mizumoto Y, Yoshiji H etal. Different roles of 8-hydroxyguanine formation and 2-thiobarbituric acid- reacting substance generation in the early phase of liver carcinogenesis induced by a choline-deficient, L-amino acid-defined diet in rats. Jpn J Cancer Res 1994; 85: 499-505.
48. Yoshiji H, Kuriyama S, Yoshii J etal. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998; 28: 1489-1496.
49. Yoshiji H, Noguchi R, Kitade M etal. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009; 44: 483-491.
50. Kaji K, Yoshiji H, Kitade M etal. Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice. Hepatol Res 2010; 40: 540-549.
51. Lee KC, Chan CC, Yang YY, Hsieh YC, Huang YH, Lin HC. Aliskiren attenuates chronic carbon tetrachloride-induced liver injury in mice. Eur J Clin Invest 2012; 42: 1261-1271.